PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

'Undruggable' mutation meets its match

6-year effort yields first drug to target important cancer gene

2013-11-21
(Press-News.org) Contact information: Jim Keeley
keeleyj@hhmi.org
301-215-8858
Howard Hughes Medical Institute
'Undruggable' mutation meets its match 6-year effort yields first drug to target important cancer gene In the field of drug design, the protein K-Ras is legendary. It's been on everyone's "target" list for more than 30 years due to its status as the most commonly mutated oncogene in human cancers. Despite this high profile, K-Ras has earned a reputation in scientific circles as being "undruggable" because many pharmaceutical, biotech, and academic laboratories have failed to design a drug that successfully targets the mutant gene. Now, Howard Hughes Medical Institute (HHMI) researchers at the University of California, San Francisco have identified and exploited a newfound "Achilles heel" in K-Ras. The weak point is a newly discovered "pocket," or binding site, identified by HHMI investigator Kevan M. Shokat and colleagues. Shokat and his team have designed a chemical compound that fits inside this pocket and inhibits the normal activity of mutant K-Ras, but leaves the normal protein untouched. "K-Ras is considered to be the most important oncogene in cancer and is widely believed to be 'undruggable,'" said Shokat. "We report the discovery of a new pocket on K-Ras that is druggable. We believe this has real translational implications for patients." In a research article published November 20, 2013, in the journal Nature, Shokat's team describes a novel chemical compound that fits into a previously unknown pocket in K-Ras and interferes with function of the enzyme. The Ras proteins are small GTPase enzymes that transmit signals within cells. They are critical to cells because of the central role they play in cell growth and survival. The name Ras also refers to the family of genes encoding those proteins. One of those genes, K-Ras, which was discovered nearly 30 years ago, is mutated in 30 percent of human tumors, including 90 percent of pancreatic cancers, 40 percent of colon cancers, and 20 percent of non-small cell lung cancers. Cancers with Ras mutations are aggressive and respond poorly to standard therapies. Despite setbacks in targeting mutant Ras genes, the National Cancer Institute (NCI) recently emphasized the continued importance of this elusive drug target by announcing a focused $10 million effort, dubbed the RAS project, to bring together researchers to develop new ideas for blocking Ras. The project aims to spur development of new drugs or therapies to benefit patients with cancer. Shokat's HHMI team, which is not part of the NCI initiative, started working on Ras in earnest about six years ago. Using their expertise in chemistry, Shokat and two team members -- Ulf Peters, a postdoctoral fellow, and Jonathan Ostrem, an MD-PhD student -- sketched out some early ideas for a new class of drugs that inhibit Ras mutants. "Some of the early strategies did not work," he said. "We had to develop a new kind of screen and that ultimately led to progress in developing this new inhibitor." Shokat says they did a few things differently when defining the scope of their attack. They kept their focus narrow, being mindful of strategies that had not worked for other scientists. They also chose to study a type of K-Ras mutant called G12C (for Glycine-12 to Cysteine), a K-Ras mutant prevalent in about seven percent of patients with lung cancer. (The K-Ras gene is mutated in 20 percent of lung cancer cases, and G12C is the most frequent mutation of K-Ras.) This mutation causes a substitution of the amino acid cysteine for glycine at position 12 in the K-Ras protein. Importantly, this cysteine sits in a location critical for the normal function of Ras. In another departure from previous efforts, Shokat and his colleagues did not try to target versions of Ras that had mutations in the amino acids aspartate and valine – which are relatively common and hence where a lot of scientists had focused their attention previously. Instead, they picked G12C mutants because those Ras mutants affected a large population of lung and colorectal cancer patients (over 20,000 new patients each year in the US alone) and because they had a cysteine substitution. Shokat says the presence of this cysteine conveyed certain chemical properties that gave his team a unique handle for drug design. Cysteine is unique among the 20 natural amino acids in its ability to form covalent bonds. Most commonly bonds are made between two cysteines to stabilize protein structure, but if a free cysteine is present, as in G12C K-Ras, a specifically designed drug can form a bond to the cysteine. "Everybody else (developing drug design strategies) had been thinking they had to go after all the Ras mutants," Shokat says. "We looked for what no else had done and we picked this particular mutation because of its chemical properties." Over a three-year period, the team developed a preliminary screen with more than 500 chemical compounds to see if they could identify one that would bind covalently and "tether" with K-Ras G12C. Their studies led to the identification of a potent inhibitor of K-Ras. To get a better picture of how this compound interacted with K-Ras, the scientists solved crystal structures of the compound bound to K-Ras. When they examined the data, Shokat and his team found a previously undescribed pocket on the surface of K-Ras near the cysteine residue. "This pocket is new," Shokat says. "No one had found it before." Investigating further, they found that the compound interferes with Ras in such a way that it alters its natural affinity for its substrate GTP, but not GDP. "One of the most important aspects of this is that this small molecule inhibits only mutant K-Ras and not the normal protein," Shokat says. Next steps include continuing to optimize this compound so that it can be further tested to see how well the compound kills cancer cells with the G12C mutation. Shokat said he and his colleagues have started a company called Araxes Pharma, LLC., which has entered into a partnership with Janssen Biotech, a division of Johnson & Johnson, to develop these compounds for potential clinical use.

### END


ELSE PRESS RELEASES FROM THIS DATE:

Drug strategy blocks a leading driver of cancer

2013-11-21
Drug strategy blocks a leading driver of cancer UCSF researchers solve decades-old challenge The protein in cells that most often drives the development of cancers has eluded scientists' efforts to block it for three decades — until now. Using ...

Long-term unemployment may accelerate aging in men

2013-11-21
Long-term unemployment may accelerate aging in men Men who are unemployed for more than two years show signs of faster ageing in their DNA, a new study has found. Researchers at Imperial College London and the University of Oulu, Finland studied DNA samples ...

Recessions experienced in mid-life linked to higher risk of cognitive decline later on

2013-11-21
Recessions experienced in mid-life linked to higher risk of cognitive decline later on Enforced job loss, part time working, and lower paid, lower status jobs may all take their toll Lay-offs and enforced part time work and lower paid, lower status jobs ...

Too much weekly sport seems to be as bad as too little for teen wellbeing

2013-11-21
Too much weekly sport seems to be as bad as too little for teen wellbeing But maximum benefit gained from double official recommendation on physical activity But the maximum benefit seems to be obtained from 14 hours of sport a week, which is double the ...

Excessive testosterone raises mortality risk in older men

2013-11-21
Excessive testosterone raises mortality risk in older men Study pinpoints optimal testosterone range for longer lifespan Chevy Chase, MD—Older men whose testosterone levels were neither low nor high tended to live longer, according to new research accepted ...

Metabolically healthy obesity does not guarantee clean bill of health

2013-11-21
Metabolically healthy obesity does not guarantee clean bill of health High BMI linked to increased risk of diabetes, cardiovascular disease Chevy Chase, MD—Obese people who are currently metabolically healthy face a higher risk of developing diabetes and ...

International Tree Nut Council funded study links nut consumption to reduced death rate

2013-11-21
International Tree Nut Council funded study links nut consumption to reduced death rate Largest study to date on nut consumption and mortality in New England Journal of Medicine In a study published today in the New England Journal of Medicine, researchers looked ...

Mount Sinai finds brain abnormalities linked to impaired self-awareness in cocaine addiction

2013-11-21
Mount Sinai finds brain abnormalities linked to impaired self-awareness in cocaine addiction Study challenges stigmatizing assumptions about cocaine addicted-individuals, points to targeted treatments based on quantifiable ...

PTSD raises risk for obesity in women

2013-11-21
PTSD raises risk for obesity in women Women with PTSD gain weight more rapidly than women without disorder Women with post-traumatic stress disorder (PTSD) gain weight more rapidly and are more likely to be overweight or obese than ...

The last croak for Darwin's frog

2013-11-21
The last croak for Darwin's frog Deadly amphibian disease chytridiomycosis has caused the extinction of Darwin's frogs, believe scientists from the Zoological Society of London (ZSL) and Universidad Andrés Bello (UNAB), Chile. Although habitat disturbance ...

LAST 30 PRESS RELEASES:

Artificial intelligence emerging as powerful patient safety tool in pediatric anesthesia

Mother’s ZIP code, lack of access to prenatal care can negatively impact baby’s health at birth, new studies show

American Society of Anesthesiologists honors John M. Zerwas, M.D., FASA, with Distinguished Service Award

A centimeter-scale quadruped piezoelectric robot with high integration and strong robustness

Study confirms that people with ADHD can be more creative. The reason may be that they let their mind wander

Research gives insight into effect of neurodegenerative diseases on speech rhythm

Biochar and plants join forces to clean up polluted soils and boost ecosystem recovery

Salk scientist Joseph Ecker awarded McClintock Prize for Plant Genetics and Genome Studies

ADHD: Women are diagnosed five years later than men, despite symptoms appearing at the same age.

Power plants may emit more pollution during government shutdowns

Increasing pressures for conformity de-skilling and demotivating teachers, study warns

Researchers develop smarter menstrual product with potential for wearable health monitoring

Microwaves for energy-efficient chemical reactions

MXene current collectors could reduce size, improve recyclability of Li-ion batteries

Living near toxic sites linked to aggressive breast cancer

New discovery could open door to male birth control

Wirth elected Fellow of American Physical Society

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: October 10, 2025

Destined to melt

Attitudes, not income, drive energy savings at home

The playbook for perfect polaritons

‘Disease in a dish’ study of progressive MS finds critical role for unusual type of brain cell

Solar-powered method lights the way to a ‘de-fossilized’ chemical industry

Screen time linked to lower academic achievement among Ontario elementary students

One-year outcomes after traumatic brain injury and early extracranial surgery in the TRACK-TBI Study

Enduring outcomes of COVID-19 work absences on the US labor market

Affirmative action repeal and racial and ethnic diversity in us medical school admissions

Cancer progression illuminated by new multi-omics tool

Screen time and standardized academic achievement tests in elementary school

GLP-1RA order fills and out-of-pocket costs by race, ethnicity, and indication

[Press-News.org] 'Undruggable' mutation meets its match
6-year effort yields first drug to target important cancer gene